80 Years of vision: preventing blindness from retinopathy of prematurity

Edward H Wood, Emmanuel Y Chang, Kinley Beck, Brandon R Hadfield, Amy R Quinn, Clio Armitage Harper 3rd, Edward H Wood, Emmanuel Y Chang, Kinley Beck, Brandon R Hadfield, Amy R Quinn, Clio Armitage Harper 3rd

Abstract

Retinopathy of prematurity (ROP) is one of the leading yet preventable causes of childhood blindness worldwide. The purpose of this review is to provide a practical template for observational and treatment methods in order to reduce the overall incidence of any ROP and to improve both short-term and long-term outcomes once Type 1 ROP (treatable ROP) develops.

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1. Delayed retinal vascular maturation following…
Fig. 1. Delayed retinal vascular maturation following anti-VEGF therapy requires surveillance.
Left eye of a child with type 1 ROP who had undergone two anti-VEGF injections at an outside hospital as an infant and did not receive follow-up with fluorescein angiography and laser until 18 months of age, disclosing continued neovascular activity with severe macular distortion. The fellow (right) eye of the child had also received three anti-VEGF injections at an outside hospital and was phthisical.

References

    1. Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74:35–49.
    1. Retinopathy of Prematurity. (accessed 18 Nov 2020).
    1. Lambert SR, Lyons CJ. Taylor and hoyt’s pediatric ophthalmology and strabismus. 5th ed. England: Elsevier Health Sciences: London; 2016.
    1. Locke JC. Retrolental fibroplasia definitive role of oxygen administration in its etiology. AMA Arch Ophthalmol. 1954;51:73–79.
    1. Szewczyk TS. Retrolental fibroplasia and related ocular diseases; classification, etiology, and prophylaxis. Am J Ophthalmol. 1953;36:1336–61.
    1. Bedrossian RH, Carmichael P, Ritter J. Retinopathy of prematurity (retrolental fibroplasia) and oxygen. I. Clinical study. II. Further observations on the disease. Am J Ophthalmol. 1954;37:78–86.
    1. Shukla A, Sonnie C, Worley S, Sharma A, Howard D, Moore J et al. Comparison of biphasic vs static oxygen saturation targets among infants with retinopathy of prematurity. JAMA Ophthalmol. 2019. 10.1001/jamaophthalmol.2018.7021.
    1. BOOST II United Kingdom Collaborative Group, BOOST II Australia Collaborative Group, BOOST II New Zealand Collaborative Group. Stenson BJ, Tarnow-Mordi WO, Darlow BA, et al. Oxygen saturation and outcomes in preterm infants. N. Engl J Med. 2013;368:2094–104.
    1. Gaynon MW, Stevenson DK, Sunshine P, Fleisher BE, Landers MB. Supplemental oxygen may decrease progression of prethreshold disease to threshold retinopathy of prematurity. J Perinatol. 1997;17:434–8.
    1. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res. 2004;79:623–30.
    1. Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G. A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology. 2009;116:513–8.
    1. Cayabyab R, Arora V, Wertheimer F, Durand M, Ramanathan R. Graded oxygen saturation targets and retinopathy of prematurity in extremely preterm infants. Pediatr Res. 2016;80:401–6.
    1. Colaizy TT, Longmuir S, Gertsch K, Abràmoff MD, Klein JM. Use of a supplemental oxygen protocol to suppress progression of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2017;58:887–91.
    1. Smith LEH. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469–73.
    1. Hellström A, Hård A-L, Engström E, Niklasson A, Andersson E, Smith L, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics. 2009;123:e638–45.
    1. Kaempf JW, Kaempf AJ, Wu Y, Stawarz M, Niemeyer J, Grunkemeier G. Hyperglycemia, insulin and slower growth velocity may increase the risk of retinopathy of prematurity. J Perinatol. 2011;31:251–7.
    1. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007;13:868–73.
    1. Wu C, Löfqvist C, Smith LEH, VanderVeen DK, Hellström A, WINROP Consortium. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol. 2012;130:992–9.
    1. Gaynon MW. Rethinking STOP-ROP: is it worthwhile trying to modulate excessive VEGF levels in prethreshold ROP eyes by systemic intervention? A review of the role of oxygen, light adaptation state, and anemia in prethreshold ROP. Retina. 2006;26:S18–23.
    1. Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–48.
    1. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991;98:1628–40.
    1. Paysse EA, Miller A, Brady McCreery KM, Coats DK. Acquired cataracts after diode laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology. 2002;109:1662–5.
    1. Vinekar A, Jayadev C, Mangalesh S, Kumar AK, Bauer N, Capone A, Jr, et al. Comparing the outcome of single versus multiple session laser photoblation of flat neovascularization in zone 1 aggressive posterior retinopathy of prematurity: a prospective randomized study. Retina. 2015;35:2130–6.
    1. Quinn GE, Dobson V, Davitt BV, Wallace DK, Hardy RJ, Tung B, et al. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6 years of age. J AAPOS. 2013;17:124–8.
    1. Lambert SR, Capone A, Jr, Cingle KA, Drack AV. Cataract and phthisis bulbi after laser photoablation for threshold retinopathy of prematurity. Am J Ophthalmol. 2000;129:585–91.
    1. Chang TC, Tran KD, Cernichiaro-Espinosa LA, Leung EH, Grajewski AL, Hodapp EA, et al. Microcornea and thickened lens in angle closure following nonsurgical treatment of retinopathy of prematurity. J Ophthalmol. 2020;2020:7510903.
    1. Trigler L, Weaver RG, Jr, O’Neil JW, Barondes MJ, Freedman SF. Case series of angle-closure glaucoma after laser treatment for retinopathy of prematurity. J AAPOS. 2005;9:17–21.
    1. Ruth A, Hutchinson AK, Baker Hubbard G. Late vitreous hemorrhage in patients with regressed retinopathy of prematurity. J AAPOS. 2008;12:181–5.
    1. Kim MJ, Kim S-J, Yu YS. The risk for retinal detachment associated with hemorrhages pre- and postlaser treatment in retinopathy of prematurity. Retina. 2008;28:1451–7.
    1. Dailey WA, Gryc W, Garg PG, Drenser KA. Frizzled-4 variations associated with retinopathy and intrauterine growth retardation: A potential marker for prematurity and retinopathy. Ophthalmology. 2015;122:1917–23.
    1. Spandau U, Larsson E, Holmström G Inadequate laser coagulation is an important cause of treatment failure in Type 1 retinopathy of prematurity. Acta Ophthalmol. 2020. 10.1111/aos.14406.
    1. Hartnett ME. Retinopathy of prematurity: evolving treatment with anti-vascular endothelial growth factor. Am J Ophthalmol. 2020;218:208–13.
    1. Toy BC, Schachar IH, Tan GSW, Moshfeghi DM. Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity. Ophthalmology. 2016;123:2166–75.
    1. Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology. 2017;124:1156–64.
    1. Sukgen EA, Koçluk Y. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2019;257:49–55.
    1. Bai Y, Nie H, Wei S, Lu X, Ke X, Ouyang X, et al. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. Br J Ophthalmol. 2019;103:494–8.
    1. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95–113.
    1. Bakbak B, Ozturk BT, Gonul S, Yilmaz M, Gedik S. Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharm Ther. 2013;29:728–32.
    1. Hong YR, Kim YH, Kim SY, Nam GY, Cheon HJ, Lee SJ. Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina. 2015;35:1772–7.
    1. Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard M-N, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137:e20153218–e20153218.
    1. Ahmed K, Ali AS, Delwadia N, Greven MA. Neurodevelopmental outcomes following intravitreal bevacizumab with laser versus laser photocoagulation alone for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retin. 2020;51:220–4.
    1. Tan Q-Q, Christiansen SP, Wang J. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review. PLoS ONE. 2019;14:e0225643.
    1. Hamad AE, Moinuddin O, Blair MP, Schechet SA, Shapiro MJ, Quiram PA, et al. Late-onset retinal findings and complications in untreated retinopathy of prematurity. Ophthalmol Retin. 2020;4:602–12.
    1. Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450–5.
    1. Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina. 2008;28:S13–8.
    1. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl J Med. 2011;364:603–15.
    1. Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, et al. A dosing study of bevacizumab for retinopathy of prematurity: Late recurrences and additional treatments. Ophthalmology. 2018;125:1961–6.
    1. Yonekawa Y, Thomas BJ, Thanos A, Todorich B, Drenser KA, Trese MT, et al. The cutting edge of retinopathy of prematurity care: expanding the boundaries of diagnosis and treatment. Retina. 2017;37:2208–25.
    1. Patel SN, Klufas MA. Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity. Eye Brain. 2019;11:25–35.
    1. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847–58.
    1. Vural A, Perente İ, Onur İU, Eriş E, Seymen Z, Hergünsel GO, et al. Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography. Int Ophthalmol. 2019;39:2161–9.
    1. Chen Y-T, Liu L, Lai C-C, Chen K-J, Hwang Y-S, Wu W-C Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity. Retina 2020. 10.1097/iae.0000000000002754.
    1. Beck KD, Rahman EZ, Ells A, Mireskandari K, Berrocal AM, Armitage Harper C III. SAFER-ROP: Updated Protocol for Anti-VEGF Injections for Retinopathy of Prematurity. 10.3928/23258160-20200702-05.
    1. Wright LM, Harper CA, 3rd, Chang EY. Management of infantile and childhood retinopathies: optimized pediatric pars plana vitrectomy sclerotomy nomogram. Ophthalmol Retin. 2018;2:1227–34.
    1. Cernichiaro-Espinosa LA, Harper CA, III, Read SP, Wright LM, Scribbick FW, III, Young R, et al. Report of safety of the use of a short 32g needle for intravitreal anti–vascular endothelial growth factor injections for retinopathy of prematurity. Retina. 2018;38:1251–5.
    1. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000–6.
    1. Yonekawa Y, Wu W-C, Nitulescu CE, Chan RVP, Thanos A, Thomas BJ, et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina. 2018;38:1079–83.
    1. Wood EH, Rao P, Moysidis SN, Dedania VS, Elman MJ, Drenser KA, et al. Fellow eye anti-VEGF “Crunch” effect in retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retin. 2018;49:e102–e104.
    1. Harper CA, 3rd, Wright LM, Young RC, Read SP, Chang EY. Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity. Retina. 2019;39:700–5.
    1. Chen TA, Shields RA, Bodnar ZH, Callaway NF, Schachar IH, Moshfeghi DM. A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity. Am J Ophthalmol. 2019;198:63–69.
    1. Kaiser RS, Trese MT, Williams GA, Cox MS., Jr Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology. 2001;108:1647–53.
    1. Park KH, Hwang J-M, Choi MY, Yu YS, Chung H. Retinal detachment of regressed retinopathy of prematurity in children aged 2 to 15 years. Retina. 2004;24:368–75.
    1. Drenser KA. Wnt signaling pathway in retinal vascularization. Eye Brain. 2016;8:141–6.
    1. Wood EH, Drenser KA, Capone A Jr. Diagnosis and management of familial exudative vitreoretinopathy: a lifelong, progressive, and often asymmetric disease. JAMA Ophthalmol. 2019. 10.1001/jamaophthalmol.2019.1484.
    1. Dejana E. The role of wnt signaling in physiological and pathological angiogenesis. Circ Res. 2010;107:943–52.
    1. John VJ, McClintic JI, Hess DJ, Berrocal AM. Retinopathy of prematurity versus familial exudative vitreoretinopathy: report on clinical and angiographic findings. Ophthalmic Surg Lasers Imaging Retin. 2016;47:14–19.
    1. Bowe T, Ung C, Campbell JP, Yonekawa Y. Telemedicine for retinopathy of prematurity in 2020. J Vitreoretin Dis. 2019;3:452–8.
    1. Beck K, Young R, Read S, Harper H, Desireddi J, Harper CA. The severity and associated comorbidities of retinopathy of prematurity among micro-premature infants with birth weights less than 750 grams. J Neonatal Perinat Med. 2019;12:41–45.
    1. Acevedo-Castellón R, Ramírez-Neria P, García-Franco R. Incidence of retinopathy of prematurity type 1 and type 2 in a regional Hospital of Social Security in the state of Queretaro, Mexico (2017-2018) BMC Ophthalmol. 2019;19:91.
    1. Senjam S, Chandra P. Retinopathy of prematurity: addressing the emerging burden in developing countries. J Fam Med Prim Care. 2020;9:2600.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner